Venatorx Pharmaceuticals - Crunchbase Company Profile & Funding

Q: Who invested in Venatorx Pharmaceuticals?

Venatorx Pharmaceuticals has 11 investors including AMR Action Fund And Abingworth.

Q: How much funding has Venatorx Pharmaceuticals raised to date?

Venatorx Pharmaceuticals has raised obfuscated.

Overview

Venatorx Pharmaceuticals

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Venatorx Pharmaceuticals

CB Rank

73445

Venatorx Pharmaceuticals develops anti-infectives to treat multi-drug-resistant bacterial infections and viral infections.

Founded

obfuscation

Private

Venture - Series Unknown

Malvern, Pennsylvania, United States

51-100

www.venatorx.com

Health Care

Medical

Pharmaceutical

Funding Rounds

Venture - Series Unknown

OBF

obfuscation

Series C

OBF

obfuscation

Grant

OBF

obfuscation

Key People

Tony Meehan, PhD: Chief Business Officer
Past Role: TetraLogic Pharmaceuticals, Chief Operating Officer
Christopher J. Burns, PhD: Founder and Senior Vice President, Biology and Grants Development

Details

Legal Name

Venatorx Pharmaceuticals, Inc.

Also Known As

Venatorx

Operating Status

Active

Company Type

For Profit

Founders

Christopher J. Burns, PhD, Luigi Xerri, PhD

About the Company

Venatorx Pharmaceuticals is a private company that focuses on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. The company was founded in 2010 and is headquartered in Malvern, Pennsylvania.

Phone Number

610-644-8935

Contact Email

contact@venatorx.com

Predictions & Insights

Growth Insight

See this Growth Insight

Venatorx Pharmaceuticals is

Lorem

to be growing

Top Contributing Factors

Operations Contraction

Products & Services

Cefepime-Taniborbactam

An intravenous combination of cefepime and taniborbactam designed to treat infections caused by multidrug-resistant Gram-negative bacteria, including carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa.

Ceftibuten-Ledaborbactam Etzadroxil

An oral prodrug combination of ceftibuten and ledaborbactam etzadroxil targeting complicated urinary tract infections caused by multidrug-resistant Enterobacterales producing serine β-lactamases.

Research & Development

Venatorx Pharmaceuticals is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Venture Round - Venatorx Pharmaceuticals	—	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Venatorx Pharmaceuticals	—	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Venatorx Pharmaceuticals	—	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Venatorx Pharmaceuticals	—	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Venatorx Pharmaceuticals	—	obfuscated obfuscation	—	Venture - Series Unknown

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Venture Round - Venatorx Pharmaceuticals	—	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Venatorx Pharmaceuticals	—	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Venatorx Pharmaceuticals	—	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Venatorx Pharmaceuticals	—	obfuscated obfuscation	—	Venture - Series Unknown
obfuscated obfuscation	Venture Round - Venatorx Pharmaceuticals	—	obfuscated obfuscation	—	Venture - Series Unknown

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
AMR Action Fund	Yes	Series C - Venatorx Pharmaceuticals	Henry Skinner, Martin Heidecker, William Burns
AMR Action Fund	Yes	Series C - Venatorx Pharmaceuticals	Henry Skinner, Martin Heidecker, William Burns
AMR Action Fund	Yes	Series C - Venatorx Pharmaceuticals	Henry Skinner, Martin Heidecker, William Burns
AMR Action Fund	Yes	Series C - Venatorx Pharmaceuticals	Henry Skinner, Martin Heidecker, William Burns
AMR Action Fund	Yes	Series C - Venatorx Pharmaceuticals	Henry Skinner, Martin Heidecker, William Burns

Market Intelligence

People

View Profiles & Contacts

Headcount

51-100

Employee Profiles

Board Members and Advisors

Contacts

Employee Profiles

Tony Meehan, PhD Chief Business Officer
Christopher J. Burns, PhD Founder and Senior Vice President, Biology and Grants Development
Manos Perros Executive Chairman of the Board
Scott McConnell Vice President, Medical Affairs